The acquisition is part of BioLife's strategy to assemble a portfolio of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets, company representatives said.

Sexton's bioproduction portfolio includes proprietary closed vials for cell therapy final-dose packaging, human platelet lysate media, a bio-defined replacement for fetal bovine serum or human serum used in cell manufacturing, and automated cell processing machines. The company's products are currently embedded in more than 50 ongoing clinical trials of new cell and gene therapies, BioLife said.

This is BioLife's sixth acquisition in the last 2.5 years.

BioLife reports revenue growth in Q2
BioLife Solutions has reported revenue growth for the second quarter of 2021.

BioLife Solutions to acquire Sexton Biotechnologies
BioLife Solutions, a supplier of cell and gene therapy bioproduction tools, plans to acquire Sexton Biotechnologies for $24 million.

BioLife Solutions launches freezer for cell and gene therapy developers
BioLife Solutions has launched a new line of high-capacity, controlled-rate freezers with a focus on the cell and gene therapy industry.

Sexton collaborates to improve flexible automation
Sexton Biotechnologies has formed a partnership with Hitech Health and Med Institute covering flexible automation for cell and gene therapy manufacturers.

BioLife Solutions invests in cell and gene therapy products
BioLife Solutions, a supplier of cell and gene therapy bioproduction tools, along with innovation accelerator partner Casdin Capital, have invested in...